Exelon
Trovati 5 articoli
- Efficacy and adverse effects of cholinesterase inhibitors and Namenda in vascular dementia
- A systematic review and meta-analysis evaluated the efficacy and safety of cholinesterase inhibitors and Memantine ( Ebixa, Namenda ) in vascular dementia. Three Donepezil ( Aricept ), two Galantamine ( Reminyl ), one Rivastigmine ( Exelon ), and two Memantine trials, comprising 3093 patients ... (Leggi Articolo)
- Exelon for treatment of dementia linked to Parkinson’s disease
- The FDA ( Food and Drug Administration ) has approved Exelon ( Rivastigmine ) for the treatment of mild to moderate dementia associated with Parkinson's disease. Exelon was previously approved for the treatment of mild to moderate dementia of the Alzheimer's type. The approval of Exelon fo... (Leggi Articolo)
- Alzheimer's drugs: Aricept, Exelon and Razadyne offer modest improvements, equal effectiveness
- The Alzheimer's drugs Aricept ( Donepezil ), Razadyne ( Galantamine ) and Exelon ( Rivastigmine ) can lead to small improvements in mental functioning and the ability to carry out everyday activities in people with mild to moderate forms of the disease, according to a review of recent studies. ... (Leggi Articolo)
- Dementia: NICE SCIE guideline to improve care
- The National Institute for Health and Clinical Excellence ( NICE ) and the Social Care Institute for Excellence ( SCIE ) have issued joint guidance on the treatment and care of people with dementia in health and social care. The guideline covers the identification, treatment and care of peop... (Leggi Articolo)
- NICE proposes to withdraw Alzheimer’s drugs from NHS
- The drugs Donepezil ( Aricept ), Rivastigmine ( Exelon ), Galantamine ( Remynil ), and Memantine ( Ebixa ) should no longer be prescribed on the National Health Service ( NHS ) to treat Alzheimer's disease according a new draft guidance from the National Institute for Clinical Excellence ( NICE )... (Leggi Articolo)
